BETTER THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.01 USD | +11.11% |
|
+61.29% | -94.87% |
| 03-21 | Better Therapeutics, Inc. Receives Notice of Default from Hercules Capital, Inc | CI |
| 03-20 | Better Therapeutics, Inc.(NasdaqCM:BTTX) dropped from S&P TMI Index | CI |
| Sales 2023 * | - | Sales 2024 * | 3.8M 304M | Capitalization | 545K 43.64M |
|---|---|---|---|---|---|
| Net income 2023 * | -28M -2.24B | Net income 2024 * | -47M -3.76B | EV / Sales 2023 * | - |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 0.14 x |
| P/E ratio 2023 * |
-0.01
x | P/E ratio 2024 * |
-0.01
x | Employees | 54 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 46.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on Better Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +11.11% | ||
| 1 week | +61.29% | ||
| Current month | -28.57% | ||
| 1 month | -27.01% | ||
| 3 months | -94.64% | ||
| 6 months | -94.76% | ||
| Current year | -94.87% |
1 week
0.01
0.02
1 month
0.010.02
Current year
0.010.27
1 year
0.011.35
3 years
0.0129.40
5 years
0.0029.40
10 years
0.0029.40
| Managers | Title | Age | Since |
|---|---|---|---|
Andres Camacho
CTO | Chief Tech/Sci/R&D Officer | - | - |
Leslie Miller
AUD | Comptroller/Controller/Auditor | 43 | 30/09/21 |
| Corporate Officer/Principal | - | 25/10/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.01 | +11.11% | 92,696 |
| 25/04/24 | 0.009 | +15.68% | 547,883 |
| 24/04/24 | 0.00778 | +29.67% | 887,792 |
| 23/04/24 | 0.006 | -1.64% | 337,042 |
| 22/04/24 | 0.0061 | -1.61% | 299,438 |
Delayed Quote OTC Markets, April 26, 2024 at 08:53 pm
More quotes
Better Therapeutics, Inc. is a prescription digital therapeutics (PDT) company. The Company is engaged in developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases. Its lead PDT product candidate, BT-001, is an investigational prescription digital therapy for the treatment of T2D. The investigational therapy is delivered via software that provides a tailored experience to patients designed to help them address the underlying causes of T2D by making meaningful, sustainable behavioral changes. The BT-001 investigational therapy is rooted in the well-studied, gold standard of behavioral modification therapies, cognitive behavioral therapy (CBT). The Company's platform consists of three behavioral therapy, treatment plans and personalization. Its behavioral therapy consists of lessons, skill- building modules, and a mechanism for goal setting. Its treatment plan is the primary engagement interface for patients.
Calendar
09/05/2024
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.01
USD
Average target price
1.5
USD
Spread / Average Target
+14,900.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -94.87% | 545K | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- BTTX Stock
